Baculi, Gemmalyn B.
HRN: 24-48-96 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/10/2024
CO-AMOXICLAV 625MG (TAB)
02/10/2024
02/17/2024
PO
625mg
BID
Lacerated Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes